LB Pharmaceuticals (LBRX) Stock Forecast, Price Target & Predictions
LBRX Stock Forecast
LB Pharmaceuticals (LBRX) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $59.78, with a high of $80.00 and a low of $35.00. This represents a 49.30% increase from the last price of $40.04.
LBRX Stock Rating
LB Pharmaceuticals stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (75.00%), 1 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).
Buy
LBRX Price Target Upside V Benchmarks
| Type | Name | Upside |
|---|---|---|
| Stock | LB Pharmaceuticals | 49.30% |
| Sector | Healthcare Stocks | 15.45% |
| Industry | Biotech Stocks | 41.48% |
Price Target Trends
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 5 | 16 |
| Avg Price Target | - | $61.60 | $50.50 |
| Last Closing Price | $40.04 | $40.04 | $40.04 |
| Upside/Downside | - | 53.85% | 26.12% |
Ratings Trends
| Date | Strong Buy | Buy | Hold | Sell | Strong Sell | Total |
|---|---|---|---|---|---|---|
| Nov, 26 | 2 | 8 | 1 | - | - | 11 |
| Oct, 26 | 1 | 7 | - | - | - | 8 |
| Sep, 26 | 1 | 7 | - | - | - | 8 |
| Aug, 26 | 1 | 7 | - | - | - | 8 |
| Jul, 26 | 1 | 5 | - | - | - | 6 |
Analyst Price Target Forecasts
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 09, 2026 | Sumant Kulkarni | Canaccord Genuity | $65.00 | $34.61 | 87.81% | 62.34% |
| Oct 05, 2026 | Guggenheim | $80.00 | $34.62 | 131.08% | 99.80% | |
| Oct 05, 2026 | Roth Capital | $35.00 | $35.95 | -2.64% | -12.59% | |
| Oct 02, 2026 | Needham | $68.00 | $37.28 | 82.40% | 69.83% | |
| Aug 24, 2026 | Raghuram Selvaraju | H.C. Wainwright | $60.00 | $47.62 | 26.00% | 49.85% |
| Aug 13, 2026 | Stifel Nicolaus | $53.00 | $45.38 | 16.79% | 32.37% | |
| Aug 12, 2026 | BMO Capital | $54.00 | $45.33 | 19.13% | 34.87% | |
| Aug 03, 2026 | Yasmeen Rahimi | Piper Sandler | $78.00 | $43.14 | 80.81% | 94.81% |
| Jul 20, 2026 | BMO Capital | $46.00 | $30.90 | 48.87% | 14.89% | |
| Jul 07, 2026 | Rudy Li | Wolfe Research | $45.00 | $33.41 | 34.69% | 12.39% |
Analyst Rating Forecasts
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 12, 2026 | H.C. Wainwright | Buy | Buy | hold |
| Oct 12, 2026 | Raymond James | Buy | upgrade | |
| Oct 05, 2026 | Guggenheim | Buy | initialise | |
| Oct 05, 2026 | Roth Capital | Buy | Neutral | downgrade |
| Oct 02, 2026 | Needham | Buy | initialise | |
| Aug 24, 2026 | H.C. Wainwright | Buy | Buy | hold |
| Aug 12, 2026 | BMO Capital | Outperform | Outperform | hold |
| Aug 03, 2026 | Piper Sandler | Overweight | Overweight | hold |
| Jul 24, 2026 | H.C. Wainwright | Buy | Buy | hold |
| Jul 20, 2026 | BMO Capital | Outperform | initialise |
Financial Forecast
EPS Forecast
Annual
| Dec 25 | Dec 26 | |
|---|---|---|
| Reported | - | - |
| Avg Forecast | $-1.91 | $-3.97 |
| High Forecast | $-1.00 | $-3.30 |
| Low Forecast | $-2.69 | $-5.27 |
| Surprise % | - | - |
Revenue Forecast
Annual
| Dec 25 | Dec 26 | |
|---|---|---|
| Reported | - | - |
| Avg Forecast | - | - |
| High Forecast | - | - |
| Low Forecast | - | - |
| Surprise % | - | - |
Net Income Forecast
Annual
| Dec 25 | Dec 26 | |
|---|---|---|
| Reported | - | - |
| Avg Forecast | $-6.76M | $-14.05M |
| High Forecast | $-3.54M | $-11.68M |
| Low Forecast | $-9.52M | $-18.65M |
| Surprise % | - | - |